Portal de investigação
Persistent Pulmonary Hypertension of the Newborn: Pathophysiological mechanisms and novel therapeutic approaches
Dados básicos
- Código:
- Estudo Clínico Académico
- Protocolo:
- Estudo Clínico Académico
- EUDRACT:
- NCT:
- Centro:
- Dotação:
- Ano de início:
- 2020
- Ano de conclusão:
Objectivos do projeto
Estudos Observacionais (STROBE statement); Natureza do Promotor: Academia – Tipo não comercial – Iniciativa do Investigador; Tipo de Centro: Unicêntrico – Cuidados Secundários
Documentos
- Não há documentos
Participantes
Unidades de investigação
Stakeholders - Promotores
Outputs do ensaio clínico
An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers
Santos-Gomes, J; (...); Bras-Silva, C
Review. 10.3389/fcvm.2022.924873. 2022
Candidate microRNAs as prognostic biomarkers in heart failure: A systematic review
Figueiredo, R; (...); Brás-Silva, C
Review. 10.1016/j.repc.2021.03.020. 2022
Editorial: Therapeutics in pulmonary arterial hypertension
Editorial Material. 10.3389/fcvm.2024.1463305. 2024
Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension
Mulvaney, EP; (...); Kinsella, BT
Article. 10.1016/j.ejphar.2020.173658. 2020
Emerging Roles of Micrornas in Veterinary Cardiology
Reis-Ferreira, A; (...); Fontes-Sousa, AP
Review. 10.3390/vetsci9100533. 2022
Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update
Vaz Salvador, P; (...); Brás-Silva, C
Review. 10.1007/s10557-021-07306-8. 2023
Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload
Lambert, M; (...); Antigny, F
Article. 10.1093/cvr/cvab016. 2021
NTP42 alleviates experimental pulmonary arterial hypertension and promotes beneficial right ventricular adaptation, preserving right heart function
Meeting Abstract. 10.1183/13993003.congress-2022.1195. 2022
Pathophysiological and therapeutic implications of urocortin-2 in heart failure with preserved ejection fraction
Adao, R; (...); Bras-Silva, C
Meeting Abstract. 2022
Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart
Willer, ASM; (...); Antigny, F
Review. 10.1113/JP284936. 2023
Pulmonary Valve Replacement: A New Paradigm with Tissue Engineering
Almeida-Pintoa, R; (...); Adao, R
Review. 10.1016/j.cpcardiol.2022.101212. 2023
The Ketone Bridge Between the Heart and the Bladder: How Fast Should We Go?
Article. 10.5213/inj.2346250.125. 2024
The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload
Mulvaney, EP; (...); Kinsella, BT
Article. 10.3389/fcvm.2022.1063967. 2022
The Thromboxane Receptor Antagonist NTP42 Promotes Beneficial Right Ventricular Adaptation and Preserves Right Heart Function in the Pulmonary Artery Banding Model of Pressure Overload
Meeting Abstract. 2022
Therapeutic Approaches in Pulmonary Arterial Hypertension with Beneficial Effects on Right Ventricular Function-Preclinical Studies
Balsa, A, Adao, R, Brás-Silva, C
Review. 10.3390/ijms242115539. 2023
Therapeutic effects of nebulization-based delivery of anti-miR-146a in experimental pulmonary arterial hypertension
Meeting Abstract. 2022
Urocortin-2 as a novel biomarker of clinical deterioration in HFpEF: a prospective cohort study
Meeting Abstract. 2024
Urocortin-2 in Acute Heart Failure: Role as a Marker of Volume Overload and Pulmonary Hypertension
Pintalhao, M; (...); Bras-Silva, C
Review. 10.1016/j.cpcardiol.2021.100860. 2022
Urocortins as biomarkers in cardiovascular disease
Vasconcelos, I; (...); Brás-Silva, C
Review. 10.1042/CS20210732. 2022
